BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
In: Blood advances, Jg. 7 (2023), Heft 12, S. 2794-2806
Online
academicJournal
Zugriff:
Titel: |
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
|
---|---|
Autor/in / Beteiligte Person: | Bonfiglio, S ; Sutton, LA ; Ljungstrom, V ; Capasso, A ; Pandzic, T ; Westrom, S ; Foroughi-Asl, H ; Skaftason, A ; Gellerbring, A ; Lyander, A ; Gandini, F ; Gaidano, G ; Trentin, L ; Bonello, L ; Reda, G ; Bodor, C ; Stavroyianni, N ; Tam, CS ; Marasca, R ; Forconi, F ; Panayiotidis, P ; Ringshausen, I ; Jaksic, O ; Frustaci, AM ; Iyengar, S ; Coscia, M ; Mulligan, SP ; Ysebaert, L ; Strugov, V ; Pavlovsky, C ; Walewska, R ; Osterborg, A ; Cortese, D ; Ranghetti, P ; Baliakas, P ; Stamatopoulos, K ; Scarfo, L ; Rosenquist, R ; Ghia, P |
Link: | |
Zeitschrift: | Blood advances, Jg. 7 (2023), Heft 12, S. 2794-2806 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 2473-9537 (print) |
DOI: | 10.1182/bloodadvances.2022008821 |
Schlagwort: |
|
Sonstiges: |
|